Is Emergent BioSolutions a good company?
Is Emergent BioSolutions a good company to work for? Emergent BioSolutions has an overall rating of 3.3 out of 5, based on over 335 reviews left anonymously by employees. 57% of employees would recommend working at Emergent BioSolutions to a friend and 42% have a positive outlook for the business.
Where are emergent BioSolutions headquarters?
Rockville, MDEmergent BioSolutions / Headquarters
What kind of company is emergent BioSolutions?
multinational specialty biopharmaceutical company
Emergent BioSolutions Inc. is an American multinational specialty biopharmaceutical company headquartered in Gaithersburg, Maryland. It develops vaccines and antibody therapeutics for infectious diseases and opioid overdoses, and it provides medical devices for biodefense purposes.
Who makes BioThrax?
El-Hibri founded Emergent in 1998. The company, then known as BioPort, had one product to its name: the anthrax vaccine BioThrax. Emergent went public in 2006.
How many people work at Emergent Biosolutions?
Emergent Biosolutions Employees Emergent Biosolutions has 2400 employees.
Who is the CEO of Emergent BioSolutions?
Robert G. Kramer Sr. (Apr 1, 2019–)Emergent BioSolutions / CEO
How many locations does Emergent BioSolutions have?
Emergent BioSolutions is headquartered in Gaithersburg, MD and has 12 offices located throughout the US.
Who owns Emergent Bio Solutions?
Fuad El-Hibri
Emergent’s founder and chairman, Fuad El-Hibri, sold shares worth $42 million during 2020, according to documents filed with the Securities and Exchange Commission. The suit also highlights some more recent stock sales — including trades in January and February by Mr.
Who is the ceo of Emergent BioSolutions?
Is BioThrax FDA approved?
BioThrax is the only FDA -licensed vaccine for the prevention of anthrax infection. It is indicated for the active immunization of adults who are at high risk of exposure to anthrax. BioThrax is manufactured from a culture filtrate, made from a non-virulent strain of Bacillus anthracis.
Who owns Bio port?
BioPort was now a subsidiary of Emergent BioSolutions, led by El-Hibri and his business partners. By the end of 2003, Emergent announced the purchase of a Maryland drug maker for more than $3 million and signed a new contract with the Pentagon, worth from $29.7 million to $245 million, depending on the doses sold.
Where is emergent located?
Gaithersburg, MD
Emergent BioSolutions is headquartered in Gaithersburg, MD and has 12 offices located throughout the US.
Is Emergent a public company?
GAITHERSBURG, Md. –(BUSINESS WIRE)–Emergent BioSolutions Inc. (NYSE:EBS) today announced the pricing of its initial public offering of 5,000,000 shares of its common stock at a price of $12.50 per share. All of these shares are being sold by the Company.
Who is the CEO of Emergent?
What kind of vaccine is BioThrax?
Anthrax vaccine adsorbed
| Vaccine description | |
|---|---|
| Target | Anthrax |
| Vaccine type | Subunit |
| Clinical data | |
| Trade names | Biothrax |
Is BioThrax a live vaccine?
VACCINE TYPE Anthrax vaccine (AVA, BioThrax), killed vaccine made from the cell-free filtrate of the nonencapsulated, attenuated strain of B. anthracis culture that contains no live bacteria (note: a live attenuated vaccine was manufactured in the former USSR, but no longer available).
Who owns Emergent Bio solutions?
Is Emergent a good stock?
Emergent BioSolutions has received a consensus rating of Moderate Buy. The company’s average rating score is 2.50, and is based on 2 buy ratings, 2 hold ratings, and no sell ratings.
What went wrong with the anthrax vaccine?
Many soldiers experienced several days of aches and pains following the administration of the vaccine, such as joint pain and other issues. Many people noted difficulty raising their arms above parallel. Headaches were a common side effect of the administration of the anthrax vaccine.